Cape Town, South Africa, November 9 (ots/PRNewswire) - - Technology Transfer Creates Sustainable Solution to Treat One of the World's Oldest and Deadliest Diseases During the annual meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD), The Lilly MDR-TB Partnership brought ...
Beijing, November 8 (ots/PRNewswire) - - Research Shows the New Test is Accurate, Simple to Run and Requires Minimal Resources Research demonstrating the potential of a special type of HPV test developed by QIAGEN with support from PATH -- a non-profit global health organization -- to reduce the incidence ...
Basel, Switzerland, November 7 (ots/PRNewswire) - - TOWARD Study, Presented at Major US Congress ACR, Confirms IL-6 Receptor Inhibition Plays a Key Role in the Treatment of RA The innovative new rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms of rheumatoid arthritis (RA) in patients who failed to ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 7 (ots/PRNewswire) - In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA. - First lipid modifying agent shown to reduce the need for treatment of the leading ...
Shire Pharmaceuticals Group Plc
Philadelphia and Basingstoke, England, November 6 (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease (CKD) patients not on dialysis.(1) FOSRENOL is a non-calcium phosphate binder, indicated to treat ...
Lyon, France, November 6 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)'s ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 6 (ots/PRNewswire) - - First Lipid Modifying Agent Shown to Reduce Risk of Leading Causes of Blindness and Deteriorating Vision in Patients With Type 2 Diabetes - Reduces Need for Laser Treatment in Patients With and Without Known Diabetic Retinopathy - Significantly Decreases Progression of Diabetic Eye Disease Fenofibrate is the ...
Orlando, Florida, November 5 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208, at the American Heart Association Scientific Meetings. The presentation titled "Oral ...
Shire Pharmaceuticals Group Plc
Basingstoke, England, November 5 (ots/PRNewswire) - - For global distribution excluding the US and Canada New data presented today at the 40th annual American Society of Nephrology (ASN) meeting and scientific exposition in San Francisco, CA, USA, show that epoetin delta - the only erythropoiesis-stimulating agent (ESA) produced in a human cell line - has ...
Amsterdam, November 5 (ots/PRNewswire) - - Highlights - Offer Price Expected to be in the Range of EUR12.50 to EUR16.00 Per Share - Offer Size Between EUR20 Million and EUR30 Million - Subscription Starts Today, 5 November 2007, and is Expected to End on 15 November 2007 - Trading on Eurolist by Euronext Amsterdam Expected to Commence on or About 16 November 2007 Avantium, a leading technology ...
Basel, Switzerland, November 5 (ots/PRNewswire) - -Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin ...
Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase III clinical trial is anticipated to begin in the second quarter of 2008 to compare the effects of prasugrel, ...
Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head-to-head TRITON TIMI-38 clinical trial, the investigational ...
Boston, November 2 (ots/PRNewswire) - - This Landmark Study Also Shows Response at 12 Weeks is a Powerful Predictor of Eventual Treatment Success. Roche today announced final results from the REPEAT study, which demonstrate that treatment with once-weekly PEGASYS(R) (peginterferon alfa-2a(40KD)) and ...
Basel, Switzerland, November 2 (ots/PRNewswire) - - Roche Progresses R1626 Into Phase IIb Study Called POLI 1 R1626, one of Roche's new investigational drugs for hepatitis C (HCV), has shown promising antiviral efficacy when given in combination with PEGASYS(R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin), according to results being presented at ...
Brussels (ots/PRNewswire) - First study to investigate the protective effect of a lipid-lowering agent on diabetic eye disease to be published on-line in Lancet, Tuesday, 6th November 2007 Diabetic eye disease (called diabetic retinopathy) is the leading cause of vision loss in adults - affecting about 25 ...
San Diego, and Indianapolis, and Cambridge, Massachusetts (ots/PRNewswire) - - U.S. New Drug Application Filing Planned by the End of the First Half of-2009 - Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results ...
Amsterdam (ots/PRNewswire) - Avantium Technologies announced today that they have signed an agreement with CRI/Criterion Inc. to enable the sale and delivery of multiple Avantium Flowrence(TM) systems. CRI/Criterion, a catalyst technology company within the Royal Dutch Shell group, is a part of a group of affiliated companies that are leading providers of catalysts, process technologies and catalyst services for a ...
Paris (ots/PRNewswire) - - Novel Compound Offers Hope to Patients not Adequately Responding to Laxative Treatment Data presented for the first time today at the international gastroenterology meeting UEGW (United European Gastroenterology Week) confirm the effectiveness and safety of RESOLOR(R) ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders re-convened earlier today, IsoTis stockholders have approved the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The acquisition is ...
Toronto (ots/PRNewswire) - Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed ...
Basel, Switzerland (ots/PRNewswire) - A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC darbepoetin-alfa (Aranesp).(1) These findings are important because to date there has been minimal data regarding SC injection ...
Irvine, California (ots/PRNewswire) - - Less Than 40,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned its special meeting of stockholders again, to Monday, October 29, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an ...
Irvine, California (ots/PRNewswire) - - Less than 100,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today reported that less than 100,000 votes "FOR" are needed to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, ...
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
Irvine, California (ots/PRNewswire) - - Less Than 350,000 Additional Votes "FOR" Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders again, to October 26, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement ...
London (ots/PRNewswire) - Data from two observational studies of over 470,000 patients taking statins in routine clinical practice investigating the incidence of cardiovascular events in patients taking CRESTOR(TM) (rosuvastatin) and other statins were presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual ...
Amsterdam (ots/PRNewswire) - - Not for release, distribution or publication into or in the United States, Australia, Canada and Japan. - Positive Results With Next Generation Biofuels Trigger IPO Plans Avantium, a leading technology company in the area of advanced high-throughput R&D, announces its intention to raise new funds through an initial public offering (the "IPO") and to apply for a listing on ...
Amsterdam (ots/PRNewswire) - - Engine Test Demonstrates Potential of "Furanics" Avantium announced today breakthrough results of the first engine tests of its novel biofuel. The technology company is developing next generation biofuel with superior economics and properties in comparison to current biofuels. By applying its advanced high-throughput R&D technology Avantium develops since a number of years a ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for a Supplemental New Drug Application (sNDA) for the indication of "Acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which ...